Floatz logo

Cladribine

PTCL

Tarapeutics Science Inc.Small moleculePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

9 Active assets in the PTCL cohort.

Asset / SponsorPhaseRating
Decitabine
Ruijin Hospital
Phase 3BB
shr2554
The First Affiliated Hospital with Nanjing Medical University
Phase 3B
Pyrotinib
Antengene Corporation
Phase 2B
rc48-adc
Antengene Corporation
Phase 2B
Zeprumetostat
Ruijin Hospital
Phase 2B

View all 13 →

Same molecule, other indications

Cladribine is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
lymphoblastic lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
multiple sclerosisDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →